Zumutor undisclosed cancer therapeutic

This entry refers to an undisclosed therapeutic candidate in the pipeline of Zumutor Biologics Inc., specifically targeting immuno-oncology and cancer. While the exact molecular target and modality are not publicly specified, the asset is part of a development program focused on Natural Killer (NK) cell-mediated therapies. Zumutor utilizes its proprietary INABLR platform to engineer monoclonal antibodies designed to enhance the recruitment and activation of NK cells against tumor targets. This molecule is currently in the early stages of development and is identified in company communications as an additional molecule for an undisclosed cell target.